TY - JOUR
T1 - κ-opioid receptor agonist suppression of HIV-1 expression in CD4+ lymphocytes
AU - Peterson, Phillip K.
AU - Gekker, Genya
AU - Lokensgard, James R.
AU - Bidlack, Jean M.
AU - Chang, An Chih
AU - Fang, Xingin
AU - Portoghese, Philip S.
N1 - Funding Information:
This work was supported, in part, by U.S. Public Health Service Grants DA09924, DA01533, K05-DA 00360, and DA04355.
Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 2001/5/1
Y1 - 2001/5/1
N2 - Synthetic κ-opioid receptor (KOR) agonists have been shown to suppress HIV-1 expression in acutely infected macrophages. In the present study, we examined the effects of the KOR ligand trans-3,4-dichloro-N-methyl-N[2-(1-pyrolidinyl)cyclohexyl]benzeneaceamide methanesulfonate (U50,488) on HIV-1 expression in CD4+ lymphocytes, the main target cell of this virus. When U50,488 was added to activated CD4+ lymphocytes, HIV-1 expression was inhibited in a concentration- and time-dependent manner with maximal suppression (≈60%) at 10-7 M U50,488. The KOR selective antagonist nor-binaltorphimine (nor-BNI) had no effect by itself on viral expression but blocked the antiviral property of U50,488, suggesting that U50,488 was acting via a KOR-related mechanism. Support for the involvement of KOR was provided by the findings that 34% of activated CD4+ lymphocytes were positive for KOR, using an immunofluorescence technique, and that seven additional synthetic KOR ligands also inhibited HIV-1 expression. The results of this study broaden understanding of the antiviral properties of KOR ligands to include cells outside of the nervous system and suggest a potential role for these agents in the treatment of HIV-1 infection.
AB - Synthetic κ-opioid receptor (KOR) agonists have been shown to suppress HIV-1 expression in acutely infected macrophages. In the present study, we examined the effects of the KOR ligand trans-3,4-dichloro-N-methyl-N[2-(1-pyrolidinyl)cyclohexyl]benzeneaceamide methanesulfonate (U50,488) on HIV-1 expression in CD4+ lymphocytes, the main target cell of this virus. When U50,488 was added to activated CD4+ lymphocytes, HIV-1 expression was inhibited in a concentration- and time-dependent manner with maximal suppression (≈60%) at 10-7 M U50,488. The KOR selective antagonist nor-binaltorphimine (nor-BNI) had no effect by itself on viral expression but blocked the antiviral property of U50,488, suggesting that U50,488 was acting via a KOR-related mechanism. Support for the involvement of KOR was provided by the findings that 34% of activated CD4+ lymphocytes were positive for KOR, using an immunofluorescence technique, and that seven additional synthetic KOR ligands also inhibited HIV-1 expression. The results of this study broaden understanding of the antiviral properties of KOR ligands to include cells outside of the nervous system and suggest a potential role for these agents in the treatment of HIV-1 infection.
KW - AIDS
KW - CD4 lymphocytes
KW - HIV
KW - Opioids
KW - U50,488
KW - κ-opioid receptor ligands
UR - http://www.scopus.com/inward/record.url?scp=0035342409&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035342409&partnerID=8YFLogxK
U2 - 10.1016/S0006-2952(01)00574-3
DO - 10.1016/S0006-2952(01)00574-3
M3 - Article
C2 - 11301048
AN - SCOPUS:0035342409
SN - 0006-2952
VL - 61
SP - 1145
EP - 1151
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 9
ER -